

# Johannes Levin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/44294/publications.pdf>

Version: 2024-02-01

223  
papers

12,548  
citations

36303

51  
h-index

32842

100  
g-index

271  
all docs

271  
docs citations

271  
times ranked

14436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284.	0.8	2
2	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
3	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
4	Seizure prevalence in neurodegenerative diseases—a study of autopsy proven cases. <i>European Journal of Neurology</i> , 2022, 29, 12-18.	3.3	6
5	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
6	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <i>NfL</i> and <i>pNfH</i> : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
7	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1754-1764.	0.8	4
8	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
9	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
10	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. <i>EMBO Journal</i> , 2022, 41, e109108.	7.8	38
11	Association of <i>BDNF</i> Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 261.	9.0	15
12	Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204.	2.3	2
13	Variant-dependent heterogeneity in amyloid $\beta^2$ burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	10.2	34
14	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
15	Data-driven staging of genetic frontotemporal dementia using multi-modal <i>MRI</i> . <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
16	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
17	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
18	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2687-2698.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
20	The <sup>CBI</sup> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
21	Serum <sup>Beta</sup>Synuclein Is Higher in Down Syndrome and Precedes Rise of <sup>pTau181</sup>. <i>Annals of Neurology</i> , 2022, 92, 6-10.	5.3	9
22	Tau deposition patterns are associated with functional connectivity in primary tauopathies. <i>Nature Communications</i> , 2022, 13, 1362.	12.8	34
23	COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. <i>Vaccines</i> , 2022, 10, 530.	4.4	8
24	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease. <i>Biomolecules</i> , 2022, 12, 458.	4.0	9
25	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2022, 21, 329-341.	10.2	72
26	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. <i>Neurobiology of Disease</i> , 2022, 168, 105714.	4.4	7
27	<sup>18</sup>F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.262854.	5.0	8
28	Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1611-1618.	2.8	3
29	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. <i>EBioMedicine</i> , 2022, 80, 104021.	6.1	26
30	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
31	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <sup>in vivo</sup> pathophysiology. <i>Brain</i> , 2022, 145, 3594-3607.	7.6	20
32	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
33	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
34	The BDNF Val66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	7.9	61
35	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.8	27
36	In Vivo Assessment of Neuroinflammation in <sup>4</sup> Repeat Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	3.9	37

#	ARTICLE	IF	CITATIONS
37	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
38	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
39	Inter-hospital transfer for mechanical thrombectomy within the supraregional stroke network NEVAS. <i>Journal of Neurology</i> , 2021, 268, 623-631.	3.6	9
40	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	2.4	11
41	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12197.	2.4	4
42	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
43	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	3.4	2
44	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. <i>European Journal of Neurology</i> , 2021, 28, 1801-1811.	3.3	11
45	Quantifying progression in primary progressive aphasia with structural neuroimaging. <i>Alzheimer's and Dementia</i> , 2021, 17, 1595-1609.	0.8	22
46	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
47	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , 2021, 144, 2176-2185.	7.6	66
48	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , 2021, 11, 239-249.	1.7	18
49	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
50	Bundle-specific associations between white matter microstructure and A $\beta$ and tau pathology in preclinical Alzheimer's disease. <i>ELife</i> , 2021, 10, .	6.0	26
51	Cortical [ <sup>18</sup> F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. <i>Movement Disorders</i> , 2021, 36, 2104-2115.	3.9	46
52	Binding characteristics of [ <sup>18</sup> F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	4.3	30
53	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	6.4	22
54	Dual-Phase $\beta$ -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	3.4	13

#	ARTICLE	IF	CITATIONS
55	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	2.4	11
56	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. <i>Neurology</i> , 2021, 97, e941-e952.	1.1	29
57	Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 103, 147.e1-147.e5.	3.1	4
58	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
59	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. <i>Frontiers in Neurology</i> , 2021, 12, 684523.	2.4	11
60	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. <i>Lancet Neurology</i> , The, 2021, 20, 615-626.	10.2	26
61	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	10.2	29
62	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	12.8	43
63	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
64	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, 1005-1016.	0.8	12
65	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
66	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
67	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	2.7	13
68	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
69	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
70	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12184.	2.4	10
71	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. <i>Science Translational Medicine</i> , 2021, 13, eabe5640.	12.4	108
72	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4582.	2.4	9

#	ARTICLE	IF	CITATIONS
73	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. <i>Journal of Clinical Medicine</i> , 2021, 10, 5125.	2.4	24
74	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
75	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
76	A data-driven disease progression model of fluid biomarkers in genetic FTD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
77	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
78	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4-repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	3.9	37
79	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. <i>Information Fusion</i> , 2020, 58, 153-167.	19.1	17
80	Drip and ship for mechanical thrombectomy within the Neurovascular Network of Southwest Bavaria. <i>Neurology</i> , 2020, 94, e453-e463.	1.1	17
81	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
82	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	3.9	42
83	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	3.3	11
84	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. <i>Journal of Neuroinflammation</i> , 2020, 17, 208.	7.2	19
85	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
86	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
87	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
88	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12038.	2.4	9
89	Assessment of <sup>18</sup> F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	9.0	145
90	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.8	35

#	ARTICLE	IF	CITATIONS
91	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
92	Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. <i>Journal of Neurology</i> , 2020, 267, 2941-2948.	3.6	38
93	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	4.4	31
94	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
95	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105924.	1.4	3
96	Binding of Metal-Ion-Induced Tau Oligomers to Lipid Surfaces Is Enhanced by GSK-3 $\beta$ -Mediated Phosphorylation. <i>ACS Chemical Neuroscience</i> , 2020, 11, 880-887.	3.5	8
97	Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI. <i>NeuroImage: Clinical</i> , 2020, 26, 102185.	2.7	18
98	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
99	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	3.9	31
100	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.8	13
101	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
102	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. <i>PLoS ONE</i> , 2020, 15, e0231495.	2.5	11
103	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
104	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
105	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, 501-511.	0.8	47
106	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
107	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	2.7	14
108	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 67.	6.2	28

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
110	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
111	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 249.	3.4	30
112	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid- $\beta^2$ processing effects. <i>Neurobiology of Aging</i> , 2019, 84, 241.e5-241.e11.	3.1	9
113	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	30.7	610
114	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. <i>Translational Psychiatry</i> , 2019, 9, 54.	4.8	28
115	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
116	Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 217-223.	2.2	6
117	Four-repeat tauopathies. <i>Progress in Neurobiology</i> , 2019, 180, 101644.	5.7	141
118	Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	87
119	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
120	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
121	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2019, 142, 1429-1440.	7.6	36
122	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
123	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 655-665.	0.8	72
124	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. <i>Cortex</i> , 2019, 117, 33-40.	2.4	17
125	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	2.0	74
126	Parkinsonism in genetic and sporadic Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 149, 237-247.	2.0	2



#	ARTICLE	IF	CITATIONS
127	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
128	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , 2019, 2, e1917126.	5.9	23
129	Increased cerebral microbleeds and cortical superficial siderosis in pediatric patients with Down syndrome. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 158-164.	1.6	8
130	A baseline study for detection of Parkinson's disease with 3D-transcranial sonography and uni-lateral reconstruction. <i>Journal of the Neurological Sciences</i> , 2019, 397, 16-21.	0.6	2
131	Different Effects of $\Delta E$ -Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1649-1659.	3.5	44
132	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 18-23.	3.1	27
133	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid- $\beta$ pathology. <i>Molecular Neurodegeneration</i> , 2019, 14, 1.	10.8	253
134	The applause sign in frontotemporal lobar degeneration and related conditions. <i>Journal of Neurology</i> , 2019, 266, 330-338.	3.6	15
135	ICP-161: 18F-P12620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	3
136	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	7.6	83
137	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	7.6	79
138	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , The, 2018, 17, 241-250.	10.2	383
139	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. <i>Lancet Neurology</i> , The, 2018, 17, 223-231.	10.2	105
140	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 41.	6.2	8
141	Three cases of isolated resting tremor of the lower limbs. <i>Basal Ganglia</i> , 2018, 11, 1-3.	0.3	1
142	Symptomatic therapy of multiple system atrophy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 211, 26-30.	2.8	18
143	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 239-247.	1.9	89
144	P1497: CLINICAL CORRELATES OF LEWY BODY PATHOLOGY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P520.	0.8	0

#	ARTICLE	IF	CITATIONS
145	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. <i>Alzheimer's and Dementia</i> , 2018, 14, P1472.	0.8	1
146	ICâ€Pâ€090: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P75.	0.8	1
147	ICâ€Pâ€067: THE BDNFVAL66MET SNP IS RELATED TO HIPPOCAMPAL CONNECTIVITY AND COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P60.	0.8	0
148	P3â€426: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1273.	0.8	0
149	<sc>CSF</sc> progranulin increases in the course of Alzheimer's disease and is associated with <sc>TREM</sc> 2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	64
150	O4â€04â€05: FIBERâ€TRACTâ€SPECIFIC DECLINE IN WHITEâ€MATTER INTEGRITY DURING THE ADULT LIFESPAN AND PRECLINICAL ALZHEIMER'S DISEASE: RESULTS FROM THE DALLAS LIFESPAN BRAIN STUDY AND DIAN. <i>Alzheimer's and Dementia</i> , 2018, 14, P1410.	0.8	0
151	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 703-713.	3.7	63
152	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. <i>Brain</i> , 2018, 141, 3065-3080.	7.6	116
153	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1427-1437.	0.8	51
154	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2018, 91, e1295-e1306.	1.1	193
155	IgLON5: A case with predominant cerebellar tau deposits and leptomenigeal inflammation. <i>Neurology</i> , 2018, 91, 180-182.	1.1	23
156	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	3.4	40
157	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	2.4	21
158	Effect of <i>BDNF</i>Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 84, 424-435.	5.3	25
159	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. <i>Current Opinion in Neurology</i> , 2018, 31, 448-454.	3.6	19
160	Multiple System Atrophy. , 2017, , 183-192.		2
161	Polyâ€sc>GP</sc> in cerebrospinal fluid links <i>C9orf72</i>â€associated dipeptide repeat expression to the asymptomatic phase of <sc>ALS</sc>/<sc>FTD</sc>. <i>EMBO Molecular Medicine</i> , 2017, 9, 859-868.	6.9	90
162	Hough-CNN: Deep learning for segmentation of deep brain regions in MRI and ultrasound. <i>Computer Vision and Image Understanding</i> , 2017, 164, 92-102.	4.7	282

#	ARTICLE	IF	CITATIONS
163	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
164	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
165	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 1225.	3.3	42
166	MR imaging differentiation of Fe <sup>2+</sup> and Fe <sup>3+</sup> based on relaxation and magnetic susceptibility properties. <i>Neuroradiology</i> , 2017, 59, 403-409.	2.2	36
167	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248.	6.4	15
168	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
169	[P4 <sup>+</sup> 189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1337.	0.8	2
170	Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. <i>Journal of Neuroimaging</i> , 2017, 27, 255-261.	2.0	23
171	Multivariate Analysis of 18F-DMFP PET Data to Assist the Diagnosis of Parkinsonism. <i>Frontiers in Neuroinformatics</i> , 2017, 11, 23.	2.5	32
172	Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 109-113.	2.2	8
173	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 440.	3.4	58
174	Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. <i>PLoS ONE</i> , 2017, 12, e0188989.	2.5	11
175	The Differential Diagnosis and Treatment of Atypical Parkinsonism. <i>Deutsches Arzteblatt International</i> , 2016, 113, 61-9.	0.9	135
176	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. <i>Frontiers in Neuroscience</i> , 2016, 10, 99.	2.8	23
177	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. <i>Science Translational Medicine</i> , 2016, 8, 369ra178.	12.4	211
178	Applied multimodal diagnostics in a case of presenile dementia. <i>BMC Neurology</i> , 2016, 16, 131.	1.8	3
179	<i>BDNF</i> Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 2766-2777.	7.6	70
180	Current Treatment of Multiple System Atrophy. <i>Current Treatment Options in Neurology</i> , 2016, 18, 51.	1.8	9

#	ARTICLE	IF	CITATIONS
181	Intracellular formation of $\alpha$ -synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 76-82.	2.1	4
182	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	2.8	32
183	Psychosis in Parkinson's disease: identification, prevention and treatment. <i>Journal of Neural Transmission</i> , 2016, 123, 45-50.	2.8	39
184	Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects. <i>Current Alzheimer Research</i> , 2016, 13, 475-486.	1.4	12
185	slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation. <i>Blood</i> , 2015, 126, 2601-2610.	1.4	116
186	Analysis of 18F-DMFP PET data using multikernel classification in order to assist the diagnosis of Parkinsonism. , 2015, , .		8
187	Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. <i>Frontiers in Computational Neuroscience</i> , 2015, 9, 137.	2.1	23
188	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. <i>Acta Neuropathologica</i> , 2015, 130, 537-555.	7.7	157
189	The association of aphasia and right-sided motor impairment in corticobasal syndrome. <i>Journal of Neurology</i> , 2015, 262, 2241-2246.	3.6	9
190	Extracellular vesicle sorting of $\alpha$ -Synuclein is regulated by sumoylation. <i>Acta Neuropathologica</i> , 2015, 129, 695-713.	7.7	136
191	Postinfectious Opsoclonus-Myoclonus Syndrome in a 41-Year-Old Patient: Visualizing Hyperactivation in Deep Cerebellar Nuclei by Cerebral [ <sup>18</sup> F]-FDG-PET. <i>Journal of Neuroimaging</i> , 2015, 25, 683-685.	2.0	9
192	Oligoclonal bands in hereditary diffuse leukoencephalopathy with spheroids. <i>European Journal of Neurology</i> , 2015, 22, e48-e48.	3.3	0
193	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. <i>Acta Neuropathologica</i> , 2015, 130, 619-631.	7.7	58
194	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. <i>PLoS ONE</i> , 2014, 9, e98906.	2.5	24
195	Onset latency of segmental dystonia after deep brain stimulation cessation: A randomized, double-blind crossover trial. <i>Movement Disorders</i> , 2014, 29, 944-949.	3.9	13
196	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. <i>Clinical Neurology and Neurosurgery</i> , 2014, 122, 113-115.	1.4	10
197	The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. <i>Acta Neuropathologica</i> , 2014, 127, 779-780.	7.7	103
198	Neurostimulation for Parkinson's Disease with Early Motor Complications. <i>New England Journal of Medicine</i> , 2013, 368, 610-622.	27.0	1,138

#	ARTICLE	IF	CITATIONS
199	Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. <i>Acta Neuropathologica</i> , 2013, 125, 795-813.	7.7	327
200	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. <i>Advances in Urology</i> , 2012, 2012, 1-10.	1.3	101
201	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. <i>Experimental Neurology</i> , 2012, 237, 470-476.	4.1	41
202	Pontine and extrapontine myelinolysis associated with hypernatraemia. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 1290-1291.	1.4	13
203	Two Different Binding Modes of $\alpha$ -Synuclein to Lipid Vesicles Depending on its Aggregation State. <i>Biophysical Journal</i> , 2012, 102, 1646-1655.	0.5	39
204	G.P.123 Identification of molecular effects of FHL1 mutations on protein assembly in reducing body myopathy. <i>Neuromuscular Disorders</i> , 2012, 22, 903.	0.6	0
205	Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with $\alpha$ -synuclein at the single molecule level. <i>Molecular Neurodegeneration</i> , 2012, 7, 35.	10.8	60
206	Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by $\alpha$ -Synuclein Oligomers in Lipid Membranes. <i>PLoS ONE</i> , 2012, 7, e42545.	2.5	75
207	Generation of Ferric Iron Links Oxidative Stress to $\alpha$ -Synuclein Oligomer Formation. <i>Journal of Parkinson's Disease</i> , 2011, 1, 205-216.	2.8	58
208	Alpha frequency modulation in the human basal ganglia is dependent on motor task. <i>European Journal of Neuroscience</i> , 2011, 33, 960-967.	2.6	27
209	Inhibition and disaggregation of $\alpha$ -synuclein oligomers by natural polyphenolic compounds. <i>FEBS Letters</i> , 2011, 585, 1113-1120.	2.8	240
210	Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 2097-2099.	3.6	4
211	Divergent Molecular Effects of Desmin Mutations on Protein Assembly in Myofibrillar Myopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 415-424.	1.7	13
212	Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 553-559.	1.5	40
213	The Value of the Dopamine D <sub>2/3</sub> Receptor Ligand <sup>18</sup> F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. <i>Journal of Nuclear Medicine</i> , 2010, 51, 581-587.	5.0	51
214	Converse modulation of toxic $\alpha$ -synuclein oligomers in living cells by N <sup>2</sup> -benzylidene-benzohydrazide derivatives and ferric iron. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 461-466.	2.1	52
215	Objective measurement of muscle rigidity in parkinsonian patients treated with subthalamic stimulation. <i>Movement Disorders</i> , 2009, 24, 57-63.	3.9	58
216	Essential tremor leading to toxic liver damage successfully treated with deep brain stimulation. <i>Acta Neurochirurgica</i> , 2009, 151, 1305-1307.	1.7	4

#	ARTICLE	IF	CITATIONS
217	Increased $\hat{\pm}$ -synuclein aggregation following limited cleavage by certain matrix metalloproteinases. <i>Experimental Neurology</i> , 2009, 215, 201-208.	4.1	80
218	Single Particle Characterization of Iron-induced Pore-forming $\hat{\pm}$ -Synuclein Oligomers. <i>Journal of Biological Chemistry</i> , 2008, 283, 10992-11003.	3.4	204
219	First symptom in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2006, 66, 286-287.	1.1	140
220	Single particle analysis of manganese-induced prion protein aggregates. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 1200-1207.	2.1	45
221	Effect of metal ions on de novo aggregation of full-length prion protein. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 1240-1246.	2.1	92
222	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
223	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2